Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in Women
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
Purpose:
The purpose of this study is to characterize the dose-proportionality in the distribution of
tenofovir alafenamide (TAF) and tenofovir (TFV) in plasma and mucosal tissues, and
TFV-diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) and mucosal tissues of
healthy female subjects following a single oral dose of GS-7430 at 5mg, 10mg, and 25mg.